JP2002542798A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542798A5
JP2002542798A5 JP2000614953A JP2000614953A JP2002542798A5 JP 2002542798 A5 JP2002542798 A5 JP 2002542798A5 JP 2000614953 A JP2000614953 A JP 2000614953A JP 2000614953 A JP2000614953 A JP 2000614953A JP 2002542798 A5 JP2002542798 A5 JP 2002542798A5
Authority
JP
Japan
Prior art keywords
polypeptide
ibd
seq
acid sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000614953A
Other languages
English (en)
Japanese (ja)
Other versions
JP4666772B2 (ja
JP2002542798A (ja
Filing date
Publication date
Priority claimed from US09/303,120 external-priority patent/US6309643B1/en
Application filed filed Critical
Publication of JP2002542798A publication Critical patent/JP2002542798A/ja
Publication of JP2002542798A5 publication Critical patent/JP2002542798A5/ja
Application granted granted Critical
Publication of JP4666772B2 publication Critical patent/JP4666772B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000614953A 1999-04-30 2000-04-28 Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法 Expired - Lifetime JP4666772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/303,120 1999-04-30
US09/303,120 US6309643B1 (en) 1999-04-30 1999-04-30 IBD-associated microbial antigens and methods of using same
PCT/US2000/011473 WO2000066067A2 (en) 1999-04-30 2000-04-28 Ibd-associated microbial antigens and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010168183A Division JP2011019515A (ja) 1999-04-30 2010-07-27 Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法

Publications (3)

Publication Number Publication Date
JP2002542798A JP2002542798A (ja) 2002-12-17
JP2002542798A5 true JP2002542798A5 (enExample) 2007-05-10
JP4666772B2 JP4666772B2 (ja) 2011-04-06

Family

ID=23170632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000614953A Expired - Lifetime JP4666772B2 (ja) 1999-04-30 2000-04-28 Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法
JP2010168183A Withdrawn JP2011019515A (ja) 1999-04-30 2010-07-27 Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010168183A Withdrawn JP2011019515A (ja) 1999-04-30 2010-07-27 Ｉｂｄ関連微生物抗原、およびｉｂｄ関連微生物抗原を使用する方法

Country Status (12)

Country Link
US (4) US6309643B1 (enExample)
EP (1) EP1187591B1 (enExample)
JP (2) JP4666772B2 (enExample)
AT (1) ATE461938T1 (enExample)
AU (1) AU767861B2 (enExample)
CA (1) CA2365898C (enExample)
DE (1) DE60044058D1 (enExample)
DK (1) DK1187591T3 (enExample)
ES (1) ES2341752T3 (enExample)
HK (1) HK1046287B (enExample)
NZ (1) NZ514887A (enExample)
WO (1) WO2000066067A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
US6821739B2 (en) * 2000-10-13 2004-11-23 The Regents Of The University Of California Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens
PT1458853E (pt) * 2002-05-16 2010-02-23 Absorber Ab Processos de prova directa de compatibilidade específicos para dadores
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) * 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2007124591A1 (en) * 2006-05-03 2007-11-08 University Of Manitoba Microbial markers of inflammatory bowel disease
US7338135B1 (en) * 2006-08-11 2008-03-04 Hall David R Holder for a degradation assembly
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US20100129838A1 (en) * 2008-11-11 2010-05-27 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
CA2758531C (en) * 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
CA2766157A1 (en) 2009-06-25 2010-12-29 Hua Gong Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
ES2530175T3 (es) 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
SG11201401536QA (en) 2011-10-21 2014-05-29 Nestec Sa Methods for improving inflammatory bowel disease diagnosis
CN103175971B (zh) * 2013-02-28 2016-10-05 苏州和锐医药科技有限公司 一种IgA抗体检测试剂盒
EP3654037A1 (en) 2013-12-03 2020-05-20 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
WO2017079653A2 (en) 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124634A1 (en) * 1996-04-30 2003-07-03 University Of Guelph Novel proteins involved in the synthesis and assembly of O-antigen in pseudomonas aeruginosa
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same

Similar Documents

Publication Publication Date Title
JP2002542798A5 (enExample)
CA2365898A1 (en) Ibd-associated microbial antigens and methods of using same
Fox et al. Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice
Fox et al. Helicobacter pylori-induced gastritis in the domestic cat
Ma et al. Epsilon toxin–producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege
US5262156A (en) Antigenic compositions and their use for the detection of Helicobacter pylori
EP1068522B1 (en) Helicobacter pylori nap protein
JP2001504684A (ja) 髄膜炎菌種の細菌に特異的なｄｎａおよび蛋白質またはペプチド、それらの取得方法およびそれらの生物学的応用
JP2006519605A5 (enExample)
CA2332570A1 (en) Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
CA2318536A1 (en) Method of and compositions for immunization with the pseudomonas v antigen
EP2178904B1 (en) Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
JP2002512800A5 (enExample)
EP1287024B1 (en) Virulence genes, proteins, and their use
Heimesaat et al. Peptidase PepP is a novel virulence factor of Campylobacter jejuni contributing to murine campylobacteriosis
Norris et al. The genus treponema
Ogunnariwo et al. Evidence for non-siderophore-mediated acquisition of transferrin-bound iron by Pasteurella multocida
JP2002501368A (ja) レプトスピラ病原体
JP4086945B2 (ja) 非毒性Ｖ．Ｃｈｏｌｅｒａｅ株の単離法およびその株由来のコレラワクチンの製造法
JP2003533990A (ja) 百日咳菌、パラ百日咳菌および気管支敗血症菌のペルタクチンの繰返し領域の多型性を有するポリペプチド、ならびに診断および免疫原性組成物におけるその使用
CA2233570C (en) Detection, prevention and treatment of papillomatous digital dermatitis
JP2001522605A5 (enExample)
JP2002519039A5 (enExample)
Porzio et al. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria
JP2008509659A5 (enExample)